MSL3L2 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 2.141200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
1.464590E-01
Normal-vs-Stage2
1.864840E-01
Normal-vs-Stage3
7.503000E-01
Normal-vs-Stage4
1.495370E-01
Stage1-vs-Stage2
5.879800E-01
Stage1-vs-Stage3
1.787770E-01
Stage1-vs-Stage4
2.753000E-01
Stage2-vs-Stage3
1.846220E-01
Stage2-vs-Stage4
8.676000E-02
Stage3-vs-Stage4
1.582600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
2.085200E-01
Normal-vs-AfricanAmerican
4.097400E-01
Normal-vs-Asian
2.180200E-01
Caucasian-vs-AfricanAmerican
9.048600E-01
Caucasian-vs-Asian
8.188600E-01
AfricanAmerican-vs-Asian
8.325600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
1.830210E-01
Normal-vs-Female
2.645600E-01
Male-vs-Female
3.308600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
2.740400E-01
Normal-vs-Age(41-60Yrs)
1.878180E-01
Normal-vs-Age(61-80Yrs)
2.284000E-01
Normal-vs-Age(81-100Yrs)
2.716200E-01
Age(21-40Yrs)-vs-Age(41-60Yrs)
6.880600E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
9.971800E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
8.152600E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
1.281020E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)
2.707000E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
6.657400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
2.249200E-01
Normal-vs-Daily Drinker
3.596800E-01
Normal-vs-Weekly Drinker
1.651590E-01
Normal-vs-Occasional Drinker
1.572420E-01
Normal-vs-Social Drinker
1.636250E-01
Non Drinker-vs-Daily Drinker
4.779400E-01
Non Drinker-vs-Weekly Drinker
4.753000E-01
Non Drinker-vs-Occasional Drinker
8.074300E-02
Non Drinker-vs-Social Drinker
4.263000E-01
Daily Drinker-vs-Weekly Drinker
8.760200E-01
Daily Drinker-vs-Occasional Drinker
3.781000E-01
Daily Drinker-vs-Social Drinker
9.223800E-01
Weekly Drinker-vs-Occasional Drinker
2.786200E-01
Weekly Drinker-vs-Social Drinker
9.525600E-01
Occasional Drinker-vs-Social Drinker
2.886600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
5.358400E-01
Normal-vs-Grade 2
1.590380E-01
Normal-vs-Grade 3
8.582000E-02
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
3.73190000000356E-05
Grade 1-vs-Grade 3
3.65190000000126E-05
Grade 1-vs-Grade 4
5.358400E-01
Grade 2-vs-Grade 3
3.972400E-01
Grade 2-vs-Grade 4
1.590380E-01
Grade 3-vs-Grade 4
8.582000E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
2.493600E-01
Normal-vs-NonDiabetic
2.100000E-01
Diabetic-vs-NonDiabetic
3.741600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
1.813230E-01
Normal-vs-NoPancreatitis
2.167600E-01
Pancreatitis-vs-NoPancreatitis
5.640600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
2.565200E-01
Normal-vs-N1
1.950970E-01
N0-vs-N1
2.425800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
5.956300E-02
Normal-vs-TP53-NonMutant
3.786800E-01
TP53-Mutant-vs-TP53-NonMutant
4.54399999960664E-07
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
